Prothena reveals positive amyloidosis data; CEO's cancer

Elan spinout Prothena said after the stock market closed on 2 December that interim Phase I/II results for NEOD001 in the treatment of amyloidosis justify initiation of a Phase III clinical trial, but the company's stock closed down 5% at $21.99 on 3 December after CEO Dale Schenk revealed that he has pancreatic cancer.

Elan spinout Prothena said after the stock market closed on 2 December that interim Phase I/II results for NEOD001 in the treatment of amyloidosis justify initiation of a Phase III clinical trial, but the company's stock closed down 5% at $21.99 on 3 December after CEO Dale Schenk revealed that he has pancreatic cancer.

Dr Schenk said in a 2 December letter to Prothena employees that his cancer was diagnosed early and he recently...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category